MT027 clinical trials
How each study uses MT027 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MT027 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Suzhou Maximum Bio-tech Co., Ltd. (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Zhejiang University (1)
Often tested with
Tested in the same studies.
Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · QH101 (1) · META10 (1) · TAEST1901 (1) · TCN 201 (1) · Base Edited Natural Killer Cells NK510 (1)
Studies
Open first, then newest update. How each study uses MT027 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07307053Written as MT027
- MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid TumorsRecruitingPhase 1Zhejiang UniversityNCT06912152Written as MT027 CAR-T cells
- Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid TumorsNot yet recruitingPhase 1Suzhou Maximum Bio-tech Co., Ltd.NCT06742593Written as MT027 cells suspension
- Study of MT027 in Patients with Recurrent or Progressive High-grade GliomaNot yet recruitingPhase 1Suzhou Maximum Bio-tech Co., Ltd.NCT06737146Written as MT027 cells suspension
- A Study of MT027 in Patients with Pleural Malignant TumorsRecruitingPhase 1Suzhou Maximum Bio-tech Co., Ltd.NCT06726564Written as MT027 cells suspension